Stem cell transplant for children and teens with acute lymphoblastic leukaemia
Tests stem cell transplants with different conditioning drugs in young patients with leukaemia.
Plain-language title generated from the registry record
Registry title: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Key facts
- Where
- Melbourne, Perth, Randwick, South Brisbane, and Sydney, AustraliaSee the 5 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with acute lymphoblastic leukaemia (ALL), other than B-ALL, who are in complete remission and need an allogeneic stem cell transplant.
- Age
- Age at diagnosis 18 years or younger. Age at transplant 21 years or younger. The registry lists 1 Month to 18 Years.
- Sex
- All sexes can join.
- Disease stage
- ALL, except B-ALL. In complete remission before the transplant. An allogeneic stem cell transplant is needed.
- Earlier treatment
- No previous stem cell transplant.
Main reasons for not taking part
- Pregnancy
- Another cancer after the leukaemia (secondary malignancy)
- A previous stem cell transplant
- Non Hodgkin-Lymphoma
- Severe other disease that does not allow treatment as in the protocol, or Karnofsky / Lansky score below 50%
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What type of cancer has the patient been diagnosed with?
- Has the patient had a stem cell transplant (a transplant of blood-forming cells from a donor or from their own body)?
- Is the patient pregnant or breastfeeding?
Source: NCT01949129, who can take part
Where in Australia
- Children's Cancer Centre The Royal Children's HospitalMelbourne, AustraliaNo longer taking part
- Princess Margaret Hospital for ChildrenPerth, AustraliaNo longer taking part
- Sydney Children's HospitalRandwick, AustraliaNo longer taking part
- Lady Cilento Children's HospitalSouth Brisbane, AustraliaNo longer taking part
- The Children's Hospital at Westmead Oncology UnitSydney, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Anna Kinderkrebsforschung
- Trial code
- NCT01949129EU 2024-512657-24-00
- Record updated
- 4 September 2026
- Original description
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.Read full original descriptionShow less
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.
The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Inclusion: Patients with ALL (except for patients with B-ALL) who fulfil the following criteria:; age at diagnosis ≤ 18 years. Age at HSCT ≤ 21 years; indication for allogeneic HSCT; complete remission (CR) before HSCT; written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"; no pregnancy; no secondary malignancy; no previous HSCT; HSCT is performed in a study participating centre.
Exclusion: severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders); patients who do not fulfil the inclusion criteria; Non Hodgkin-Lymphoma; the whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian; no consent is given for saving and propagation of anonymous medical data for study reasons; Karnofsky / Lansky score < 50%; subjects unwilling or unable to comply with the study procedures.